The Covid-19 vaccine developed by Pfizer and BioNTech - and currently used in Singapore - can be quickly modified if the virus mutates to the extent that the vaccine is no longer effective against it, said BioNTech's chief strategy officer and managing director Ryan Richardson.
At present, however, a preliminary study has showed that the shot appears to be effective against the more infectious coronavirus strains that surfaced in Britain and South Africa.
"The technology is very well suited to quick modifications," said Mr Richardson, referring to the messenger RNA platform the vaccine uses. "In a period of weeks, we would be able to produce a new vaccine variant to potentially address a new strain," he said in an interview with The Sunday Times.
BioNTech co-founder Ugur Sahin also told a news conference last month that its vaccine can be adapted in six weeks.
Mutations in the virus refer to random changes in its genetic sequence. These changes can be introduced as the virus replicates - akin to how typographical errors are introduced as a text is copied and pasted.
Messenger RNA vaccines such as the ones developed by Pfizer-BioNTech and Moderna - another leading vaccine candidate - involve injecting snippets of the viral genetic sequence into the body to trigger an immune response.
"In principle, the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation - we could be able to provide a new vaccine within six weeks," Dr Sahin said.
Their assurances come as nations scramble to contain outbreaks of the more infectious strains of the coronavirus which appeared in South Africa and Britain.
According to a preliminary study by Pfizer and the University of Texas Medical Branch published on preprint site bioRxiv on Thursday, the vaccine appears to be effective against both.
Mr Richardson said during last week's interview that there is a risk that future variants could challenge the effectiveness of the vaccine, however this is something being closely monitored.
"(Adapting the vaccine) is something that over the longer term will be an important part of staying on top of Covid-19 and making sure that the mutation does not take us backwards," he said.
The Covid-19 vaccine by Pfizer-BioNTech is the first and only vaccine to be approved for use in Singapore so far. The first shipment arrived here last month, making the Republic the first nation in Asia to receive the doses.
Asked when other shipments of the vaccine are due to arrive, Mr Richardson said: "I can say confidently that we plan to send doses throughout 2021."
Doses will come in instalments worldwide, he said, adding that BioNTech and Pfizer are working to expand capacity. "So I expect that our supply capacity will continue to ramp up throughout the first half of this year," he said.
He added that even though Singapore is a small market in and of itself, the company sees the country as an "important part of a broader strategic region... namely the neighbouring South-east Asia region".
"We're proud that we were the first company to bring a vaccine to Singapore. For us, Singapore is an important region and we plan to establish a presence in Singapore going forward," he said.
